{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:14:07Z","timestamp":1763968447639,"version":"3.45.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":33,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ahjo.2021.100057","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T19:29:22Z","timestamp":1634066962000},"page":"100057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease?"],"prefix":"10.1016","volume":"9","author":[{"given":"Bahadir","family":"Simsek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-9913","authenticated-orcid":false,"given":"Bugra Han","family":"Egeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atakan","family":"Selte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibin","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6061-0706","authenticated-orcid":false,"given":"Erin","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2021.100057_bb0005","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Collaborators GDaI","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ahjo.2021.100057_bb0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How common is residual inflammatory risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.ahjo.2021.100057_bb0015","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2021.100057_bb0020","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2021.100057_bb0025","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2021.100057_bb0030","first-page":"1","article-title":"Gout pharmacotherapy in cardiovascular diseases: a review of utility and outcomes","author":"Kaul","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ahjo.2021.100057_bb0035","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2021.100057_bb0040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/01.CIR.0000080895.05158.8B","article-title":"Statins promote potent systemic antioxidant effects through specific inflammatory pathways","volume":"108","author":"Shishehbor","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100057_bb0045","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the american College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100057_bb0050","first-page":"179","article-title":"Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells","volume":"124","author":"Libby","year":"1986","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ahjo.2021.100057_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000331580","article-title":"Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?","volume":"223","author":"Mueller","year":"2011","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1016\/j.ahjo.2021.100057_bb0060","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100057_bb0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ahjo.2021.100057_bb0070","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ahjo.2021.100057_bb0075","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2021.100057_bb0080","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","article-title":"Update on colchicine, 2017","volume":"57","author":"Slobodnick","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.ahjo.2021.100057_bb0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41580-018-0009-y","article-title":"Microtubule dynamics: an interplay of biochemistry and mechanics","volume":"19","author":"Brouhard","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ahjo.2021.100057_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.616","article-title":"Introducing variability in targeting the microtubules: review of current mechanisms and future directions in colchicine therapy","volume":"8","author":"Forkosh","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ahjo.2021.100057_bb0095","first-page":"1","article-title":"Gout pharmacotherapy in cardiovascular diseases: a review of utility and outcomes","author":"Kaul","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ahjo.2021.100057_bb0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ahjo.2021.100057_bb0105","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ahjo.2021.100057_bb0110","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2013.08.726","article-title":"Colchicine and the heart: pushing the envelope","volume":"62","author":"Deftereos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100057_bb0115","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100057_bb0120","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT)","volume":"41","author":"Bouabdallaoui","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2021.100057_bb0125","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100057_bb0130","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","article-title":"Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial","volume":"13","author":"Shah","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ahjo.2021.100057_bb0135","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100057_bb0140","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/CIRCULATIONAHA.120.051240","article-title":"Colchicine for secondary cardiovascular prevention in coronary disease","volume":"142","author":"Roubille","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2021.100057_bb0145","first-page":"1722","article-title":"Colchicine use and incident coronary artery disease in male patients with gout","volume":"36","author":"Shah","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ahjo.2021.100057_bb0150","first-page":"1697","article-title":"Will colchicine soon be part of primary and secondary cardiovascular prevention?","volume":"36","author":"Samuel","year":"2020","journal-title":"Can. J. Cardiol."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602221000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602221000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:27:24Z","timestamp":1763000844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602221000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"alternative-id":["S2666602221000550"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2021.100057","relation":{},"ISSN":["2666-6022"],"issn-type":[{"type":"print","value":"2666-6022"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease?","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2021.100057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100057"}}